HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.
about
Dual Inhibitor AEE788 Reduces Tumor Growth in Preclinical Models of MedulloblastomaA paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyTargeting of erbB3 receptor to overcome resistance in cancer treatmentRegulation of ERBB3/HER3 signaling in cancerAn Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or NeuregulinCellular effects of HER3-specific affibody moleculesPhase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.Molecular Signaling of Progesterone, Growth Hormone, Wnt, and HER in Mammary Glands of Dogs, Rodents, and Humans: New Treatment Target Identification.Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells.Post-transcriptional mechanisms contribute to the suppression of the ErbB3 negative regulator protein Nrdp1 in mammary tumors.High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116EGFR signaling in breast cancer: bad to the bone.E3 ubiquitin ligases in ErbB receptor quantity control.Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistanceRole of E542 and E545 missense mutations of PIK3CA in breast cancer: a comparative computational approach.Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology.Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3.Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes.Combining anti-ERBB3 antibodies specific for domain I and domain III enhances the anti-tumor activity over the individual monoclonal antibodiesCombating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab.Anti-tumor efficacy of naked siRNAs for ERBB3 or AKT2 against lung adenocarcinoma cell xenografts.The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 PositiveParacrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal MelanomaStructural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutationsHER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-AnalysisPhosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrinAnti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells.Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with TrastuzumabInhibition of the HER2 pathway by n-3 polyunsaturated fatty acids prevents breast cancer in fat-1 transgenic mice.New developments in the treatment of ovarian cancer--future perspectives.
P2860
Q24615472-BD83C3B6-8731-4BDE-A231-9A123054759DQ26824462-809EAA79-5040-4F2B-B989-89EA6174987FQ26864668-748B67E7-A66F-41A6-AA04-E79E2607A960Q27024334-D658007D-214A-433B-848A-27C0257B930EQ27679463-7062840A-BFE7-4883-9F6C-037C1FB1B5BEQ28727774-DEA86C05-EA8B-4192-BEC2-8FD86D095D7CQ33412770-A6739E1D-370A-40C3-A586-E823B4288432Q33559178-DA53B7A1-8D0F-4D0B-9072-0F657FB594A3Q33891230-6B445C51-EA8C-4C13-9702-E9EC5CB8F1A3Q34104165-C217DE5E-C563-445E-9B93-26F6FD5924AAQ34121278-130CCAD8-748B-40BB-9184-D1F305098AB1Q34128962-4165B2E6-2872-493A-9402-C910F543F1FAQ34223890-9FC7EA82-2F73-4162-A520-C999284BDAA8Q34348232-4A2B673D-9E19-402D-9484-2C02641229ABQ34349106-6D789E36-DA0A-4E6C-9D3A-3A4619C0A25AQ34355748-1E999D56-6703-4F65-858E-F50CE7D742CBQ34539092-2C132E93-1C69-4182-A7BB-53BD7938930BQ34735615-B2AA2C29-B5D9-4696-A33B-95267FC0D58CQ34949789-8DE682B8-C8F5-4410-A330-7755B041393EQ35145024-56AA6683-859A-4844-837D-0C2FB35AB4FFQ35409548-1307C02B-E427-4839-9CFA-3CB50538F776Q35506684-157E79BE-FCE9-422E-BF86-B042399C29B5Q35563891-7A3BAF87-A428-44A8-9DD3-C4D16BEF8C3AQ35584314-E250BD05-9AAD-4577-91A6-B6D4BBF4B45BQ35812023-3E5187F4-2774-4A60-9FFC-9A9FF13596B9Q35812275-E36ADA23-A5DE-4711-92A2-B113EAAF8D6DQ35820920-98E04991-1D98-4EBE-8C23-A80EE54D9544Q36106546-0160B321-3FE6-40A5-989E-23D559D9E64EQ36311874-78D44791-02D8-46D4-848D-1823D268ADC8Q36547753-8D1DFCB8-4A73-418D-B2CD-99B3BEF7B838Q36619622-F91EE186-8311-497E-A40A-63EA6A53A581Q36670915-75EAA097-1C17-42D6-B704-B44B6C4FC0B5Q36772036-EDD0B917-B986-4782-A68E-D5B08216AE4CQ36780754-6B78DBA4-28AF-4A25-86E5-AB2363B03064Q36793441-29137D2E-BC69-49F3-93A2-7E79801102ABQ36797398-58E22A8B-8FAE-4BD2-93FA-A050DAEFBD0CQ37044197-5EFDF637-779C-4EE0-B1FB-4B9647AF2C49Q37148772-2AEDA0CD-82A9-461F-BD80-A8E9B561059CQ37305409-3B535A10-34E8-443B-931E-3F162CAFF3D1Q37332487-6DE6EE86-AEBC-40EB-86C2-0850EEF58E3B
P2860
HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
HER3 comes of age: new insight ...... r biology, and cancer therapy.
@en
HER3 comes of age: new insight ...... r biology, and cancer therapy.
@nl
type
label
HER3 comes of age: new insight ...... r biology, and cancer therapy.
@en
HER3 comes of age: new insight ...... r biology, and cancer therapy.
@nl
prefLabel
HER3 comes of age: new insight ...... r biology, and cancer therapy.
@en
HER3 comes of age: new insight ...... r biology, and cancer therapy.
@nl
P2093
P2860
P1476
HER3 comes of age: new insight ...... r biology, and cancer therapy.
@en
P2093
Dhara Amin
Marcia R Campbell
Mark M Moasser
P2860
P304
P356
10.1158/1078-0432.CCR-09-1218
P407
P577
2010-02-23T00:00:00Z